Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy.
There is no known clinical association between chronic myelogenous leukemia (CML) and membranoproliferative glomerulonephritis (MPGN). We present a patient who was followed in the renal clinic for proteinuria of unknown etiology (3.2 g/24 h) and normal renal function who was diagnosed with CML as well as MPGN and acute renal failure at the same time. The patient's renal function and proteinuria improved when his CML was treated with imatinib mesylate, suggesting that CML either caused or exacerbated existing MGPN. To the best of our knowledge, this is the first reported case of MPGN associated with CML that improved with imatinib mesylate therapy.
Dwyer
J P
JP
Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Yates
K M
KM
Sumner
E L
EL
Stone
W J
WJ
Wang
Y
Y
Koury
M J
MJ
Fogo
A B
AB
Zent
R
R
D001549:Benzamides; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D018450:Disease Progression; D005500:Follow-Up Studies; D050533:Glomerular Basement Membrane / Q000648:ultrastructure; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000473:pathology; D008297:Male; D050527:Mesangial Cells / Q000648:ultrastructure; D008854:Microscopy, Electron; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases